Skip to main content
Fig. 2 | Journal of Hematology & Oncology

Fig. 2

From: Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers

Fig. 2

T-cell activation marker analysis for CD69 (late activation marker) and CD25 (early activation marker) as well as cytokine release. T-cell activation after 48 h of incubation in the TDCC assay was assessed using SK-CO-1, MKN-45, and H2122. Cytokine and granzyme B release in supernatants from TDCC is exemplarily shown for SK-CO-1. BsAb, bispecific antibody

Back to article page